As the inventor of SLT, Lumenis is proud to share the results of the LiGHT trial: a robust and randomized controlled study with over 700 patients across 6 hospitals that declared Lumenis-developed SLT technology as the most effective first-line treatment for glaucoma. With intraocular pressure stability superior to drops and just as safe, SLT is the standard of care for glaucoma first-line therapy. https://bit.ly/2FgeUOm #Ophthalmology #SLT #GlaucomaWeek #Lumenis | Lumenis Vision